IUPS/APS Newsroom March 29-April 6
San Diego Convention Center
Hall E Registration Area/Flex Unit
Telephone: 619.525.6228
Contact: Donna Krupa
(703) 967-2751 (cell)
(301) 634-7209 (office, outside IUPS dates)
Adding Growth Factor To Baby
Formula Could Reduce NEC, The Most Common, Devastating GI Disease In
Preemies
Incidence among formula-fed infants sharply higher
San Diego (April 3, 2005) – Could it be that the most
widespread and devastating gastrointestinal disease affecting premature
babies could be conquered simply by adding a common
polypeptide, epidermal growth factor (EGF), to infant formula? And if
so, exactly how does it work, and why?
Necrotizing enterocolitis (NEC) affects some 10,000
infants annually in the U.S., and over 90% are formula-fed before onset of
NEC. At greatest risk are small, premature infants, and infants fed
concentrated formulas. Estimates of mortality vary widely, up to 40%.
International rates of incidence and mortality are thought to be similar.
Although there is no effective treatment, the incidence
of NEC among formula-fed babies is estimated at six to 10 times higher than
breast-fed babies, indicating important direct benefits of mother’s milk.
“Using a neonatal animal model of NEC, we have shown
that when one protein found in breast milk -- epidermal growth factor (EGF)
-- is added to formula, the incidence of NEC decreases by 50% compared to
animals fed formula alone,” Jessica A. Clark, the lead author in a research
study at the Department of Pediatrics, University of Arizona, said.
“Under conditions designed to induce NEC in neonatal
rats, we found that EGF treatment alters the balance of cell death and cell
survival gene expression so that neonatal intestinal cells are able to
survive, short-circuiting the usual NEC progression, and enabling normal
intestinal growth,” Clark added.
*Paper presentation: “Epidermal growth
factor reduces intestinal apoptosis in an experimental model of necrotizing
enterocolitis,” 12:30 p.m.-3 p.m. Sunday April 3, Physiology 400.1/board
#A865. On view 7:30 a.m. - 4 p.m. Clark is presenting the research at
the 35th Congress of the International Union of Physiological Sciences in
San Diego, March 31 - April 5, 2005.
The complete team includes: Jessica A. Clark, Tara A.
Saunders, Sarah M. Doelle, Hana Holubec, Robert H. Lane, Melissa D. Halpern
and Bohuslav Dvorak, all from the Department of Pediatrics, University of
Arizona, Tucson.
Finding how EGF protects intestinal cells
“Since there is currently no effective preventative
treatment for NEC, it is essential that we understand the molecular
mechanism of EGF protective or healing effects so that an adequate human
therapy can be developed,” Clark said. In the meantime, she added,
“development should start right away of an infant formula fortified with
growth factors such as EGF.”
The current experiment was designed to see if EGF could
protect enterocytes from apoptosis, or cell death, prior to the full onset
of NEC. The Bcl-2 family of proteins is an important class of molecules that
regulates intestinal cell apoptosis. Gene expression of two major Bcl-2
family members, Bcl-2 and Bax were measured after neonatal rats were exposed
to conditions that induce NEC. Three groups of neonatal rats were involved:
dam-fed (DF), formula fed (NEC) and formula plus 500 ng/ml EGF (NEC+EFG).
Researchers found that Bc1-2 mRNA was reduced and Bax
mRNA was elevated in NEC compared to DF (p
£ .01). EGF increased Bc1-2 mRNA while Bax mRNA was decreased (p
£ 0.05). Bax/Bc1-2 mRNA and protein
were markedly decreased in NEC+EGF animals compared to the NEC group.
Cleaved caspase-3 positive epithelial cells, indicating cells undergoing
apoptosis, were reduced in EGF-treated animals compared to animals with NEC
(p £ 0.001).
“The most exciting finding was that EGF treatment
altered the balance of cell death and cell survival gene expression such
that the intestinal cells are able to survive,” Clark said. “In other words,
we saw that the breast milk protein EGF protects the intestine from
developing NEC.” Therefore, supplementing commercially available infant
formula with EGF may be one way to prevent NEC in human babies.
Next steps and funding
Clark said that the next step “will be to further
understand the molecular mechanism of the EGF healing effect in NEC, such as
the EGF receptor signaling cascades that are used to promote cell survival.
We are currently working on developing an in vitro system, using
cultured intestinal epithelial cells, to study these signaling cascades.”
Research was supported by an American Physiological
Society Porter Physiology Fellowship (Clark) and by the National Institutes
of Health (Dvorak).
***
The 35th Congress of the International Union of
Physiological Sciences is in San Diego, March 31 - April 5, 2005. The
Congress (http://www.iups2005.org/)
is organized by the six member societies of the U.S. National Committee of
the IUPS,
the American Physiological Society,
the Society for Neuroscience,
the Microcirculatory Society,
the Society of General Physiologists,
the Biomedical Engineering Society, and
the Society for Integrative and Comparative Biology, under the auspices
of the U.S. National Academy of Sciences.
The IUPS conference, held every four years, runs
concurrently this year with Experimental Biology 2005 at the San Diego
Convention Center.
The American Physiological Society (APS), which is
hosting IUPS, was founded in 1887 to foster basic and applied science, much
of it relating to human health. The Bethesda, MD-based Society has more than
10,000 members and publishes nearly 4,000 articles every year in its 14
peer-reviewed journals. In May, APS received the Presidential Award
for Excellence in Science, Mathematics and Engineering Mentoring (PAESMEM).
***
Editor’s Note: For further information or to
schedule an interview with a member of the research team, please contact
Donna Krupa at the IUPS/APS newsroom @ 619.525.6228 (March 31-April
6), or (703) 967-2751 (cell) or (301) 634-7209 (office), or Stacy Brooks at
240.432.9697 (cell) or 301.634.7253 (office).
A searchable online program for IUPS and EB is at
http://www.faseb.org/meetings/eb2005/call/default.htm